1. Home
  2. NAMS vs KYN Comparison

NAMS vs KYN Comparison

Compare NAMS & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • KYN
  • Stock Information
  • Founded
  • NAMS 2019
  • KYN 2004
  • Country
  • NAMS Netherlands
  • KYN United States
  • Employees
  • NAMS N/A
  • KYN N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • KYN Finance/Investors Services
  • Sector
  • NAMS Health Care
  • KYN Finance
  • Exchange
  • NAMS Nasdaq
  • KYN Nasdaq
  • Market Cap
  • NAMS 2.5B
  • KYN 2.1B
  • IPO Year
  • NAMS N/A
  • KYN N/A
  • Fundamental
  • Price
  • NAMS $23.60
  • KYN $12.20
  • Analyst Decision
  • NAMS Strong Buy
  • KYN
  • Analyst Count
  • NAMS 9
  • KYN 0
  • Target Price
  • NAMS $41.11
  • KYN N/A
  • AVG Volume (30 Days)
  • NAMS 844.8K
  • KYN 561.5K
  • Earning Date
  • NAMS 08-06-2025
  • KYN 01-01-0001
  • Dividend Yield
  • NAMS N/A
  • KYN 8.99%
  • EPS Growth
  • NAMS N/A
  • KYN N/A
  • EPS
  • NAMS N/A
  • KYN 0.71
  • Revenue
  • NAMS $47,140,000.00
  • KYN N/A
  • Revenue This Year
  • NAMS N/A
  • KYN N/A
  • Revenue Next Year
  • NAMS N/A
  • KYN N/A
  • P/E Ratio
  • NAMS N/A
  • KYN $13.79
  • Revenue Growth
  • NAMS 586.97
  • KYN N/A
  • 52 Week Low
  • NAMS $14.06
  • KYN $7.84
  • 52 Week High
  • NAMS $27.29
  • KYN $9.88
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 67.01
  • KYN 42.70
  • Support Level
  • NAMS $22.00
  • KYN $12.13
  • Resistance Level
  • NAMS $24.82
  • KYN $12.66
  • Average True Range (ATR)
  • NAMS 1.21
  • KYN 0.16
  • MACD
  • NAMS 0.25
  • KYN -0.03
  • Stochastic Oscillator
  • NAMS 77.98
  • KYN 13.21

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: